Cross-protectivity of henipavirus soluble glycoprotein in an in vivo model of Nipah virus disease
Open Access
- 26 February 2025
- journal article
- immunology
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1517244
Abstract
Introduction: Nipah virus (NiV) is one of a group of highly pathogenic viruses classified within the Henipavirus genus. Since 2012 at least 11 new henipa-like viruses have been identified, including from new locations and reservoir hosts; the pathogenicity of these new viruses has yet to be determined, but two of them have been associated with morbidity, including fatalities.Methods: The efficacy and cross-reactivity of two vaccine candidates derived from the soluble glycoproteins of both NiV and Hendra virus (HeV) was evaluated in our recently established hamster model.Results: Both vaccine preparations resulted in strong humoral responses against NiV antigenic targets, demonstrating cross-reactive immunity. Efficacy was determined through challenge of hamsters with NiV Malaysian (NiV-M) strain. 100% of the hamsters survived a lethal challenge dose after prime/boost immunisation with glycoproteins derived from both NiV and HeV in the presence of adjuvant, with clinical signs and pathology being significantly reduced in immunised animals.Discussion: This is first time the NiV and HeV soluble glycoproteins have been compared in the NiV-M hamster challenge model in the presence of Alhydrogel and AddaVax, providing evidence that glycoproteins from closely related henipavirus species can provide cross-protectivity against infection from alternate henipaviruses, supporting the potential of an effective pan-henipavirus vaccine for use in a frontline outbreak response.Keywords
Funding Information
- UK Research and Innovation
This publication has 53 references indexed in Scilit:
- Chimeric vaccine design against the epidemic Langya Henipavirus using immunoinformatics and validation via immune simulation approachesHeliyon, 2023
- Hendra VirusVeterinary Clinics of North America: Equine Practice, 2023
- The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development effortsAntiviral Research, 2018
- Syrian Hamsters as a Small Animal Model for Emerging Infectious Diseases: Advances in Immunologic Methods2016
- Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamstersAntiviral Research, 2014
- Immunization Strategies Against Henipaviruses2012
- A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in catsVaccine, 2008
- Specific detection of Nipah virus using real-time RT-PCR (TaqMan)Journal of Virological Methods, 2004
- High mortality in Nipah encephalitis is associated with presence of virus in cerebrospinal fluidAnnals of Neurology, 2000
- MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines1995